PetVivo Holdings, Inc. (PETV) SEC Filings

PetVivo Holdings, Inc. (PETV) reported that its Chief Executive Officer and director John Lai acquired 31,250 shares of restricted common stock on September 9, 2026 at $0.78 per share in connection with a private placement investment pursuant to a subscription agreement. In a related step, on September 8–9, 2026 he converted warrants covering 31,250 shares of common stock at an exercise price of $1.10 per share, with the warrants scheduled to expire on September 9, 2029. Following these transactions, he directly holds 2,413,163 shares of PetVivo common stock. No transactions were reported under a Rule 10b5-1 trading plan.

PetVivo Holdings, Inc. (PETV) announced that its representatives plan to use an updated investor presentation in meetings with investors, analysts and at conferences. The presentation, dated August 2026, is furnished as Exhibit 99.1 to this current report.

The company states that this information is being provided under Regulation FD and Item 7.01 and is considered "furnished," not "filed," which limits potential liability under the Exchange Act and affects incorporation by reference into other securities filings. PetVivo may update or modify the presentation over time, including through future SEC reports, press releases or its corporate website.

PetVivo Holdings, Inc. reported unaudited results for the three months ended June 30, 2026. Revenue was $337,572, up from $297,500 a year earlier, driven largely by distributor Vedco, which accounted for about 70% of sales, and Clipper, at about 12%.

Gross profit was $223,317. Operating expenses were $1,832,166, leading to an operating loss of $1,608,849 and a net loss of $1,613,888, an improvement versus a $2,311,037 net loss in the prior-year quarter. Net cash used in operating activities was $965,779. Cash declined to $122,633 and total assets to $2,669,481, with stockholders’ equity of $1,356,169 and an accumulated deficit of $103,051,394.

The company corrected prior accounting for a June 30, 2025 convertible note amendment by removing a $763,259 beneficial conversion feature in line with ASU 2020‑06; this changed equity classifications but did not affect prior revenue or net loss. Management concluded that recent losses, low cash, and dependence on external financing raise substantial doubt about the ability to continue as a going concern. Subsequent events include additional non-convertible debt financing and formal termination of the VetStem PrecisePRP licensing agreement.

PetVivo Holdings, Inc. shareholder Alexander Nazarenko reports beneficial ownership of 8,044,085 PetVivo securities, representing 18.73% of the issuer’s outstanding common and preferred shares as of July 22, 2026. This includes 2,045,081 shares with sole voting and dispositive power and 5,999,004 shares with shared voting and dispositive power, held directly, by his spouse, and through entities he controls. He also holds 1,011,985 warrants that are currently excluded from the ownership calculation under SEC Rule 13d-3(d)(1). Nazarenko states the holdings were not acquired for the purpose of changing or influencing control of PetVivo and that he is not the beneficial owner of 20% or more of the class.

PetVivo Holdings, Inc. terminated its Exclusive License and Supply Agreement with VetStem, Inc. for the PrecisePRP® product line through a Termination and Settlement Agreement effective July 24, 2026. All exclusive rights under the prior license reverted to VetStem, remaining PrecisePRP® inventory transferred to VetStem, and the parties exchanged mutual releases covering substantially all claims arising under the license, fully resolving related disputes.

Under the settlement, PetVivo’s sole stated financial obligation is aggregate cash payments of $75,000, with $50,000 due within 14 days of the effective date and $25,000 due within 30 business days, plus any additional amount that may arise from an inventory reconciliation mechanism. A warrant held by VetStem to purchase 250,000 PetVivo common shares remains outstanding on its existing terms. The company states that this resolution allows it to concentrate resources on its proprietary technologies, including SPRYNG® with OsteoCushion® Technology, and broader strategic initiatives.

PetVivo Holdings, Inc. reported a change in its independent auditors. Stephano Slack LLC resigned as the company’s independent registered public accounting firm, effective July 2, 2026, after auditing the fiscal years ended March 31, 2026 and March 31, 2025. Those audit reports contained no adverse or disclaimed opinions and were not qualified, but the 2026 report included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, which is treated as a reportable event. The company states there were no disagreements with Stephano Slack on accounting or auditing matters.

On July 23, 2026, with Audit Committee approval, PetVivo engaged GuzmanGray, A Professional Accountancy Corporation, as its new independent registered public accounting firm for the fiscal year ending March 31, 2027, including interim review periods ending June 30, September 30, and December 31, 2026. PetVivo reports it had not previously consulted GuzmanGray on accounting, auditing, or financial reporting issues.

PetVivo Holdings, Inc. reported that Chief Financial Officer Garry N. Lowenthal indirectly acquired 75,000 shares of restricted common stock on 2026-07-21 at $0.77 per share. The grant was issued to a corporation he owns as compensation for past performance, bringing his indirect "By Corporation" holdings to 953,881 shares.

Lai John reported acquisition or exercise transactions in this Form 4 filing.

PetVivo Holdings, Inc. reported that Chief Executive Officer John Lai, through a corporation he owns, received a grant of 75,000 shares of restricted common stock on July 21, 2026 at $0.77 per share as compensation for past performance, increasing his indirectly held common stock to 2,381,913 shares.

PetVivo Holdings, Inc. files its annual report describing an emerging veterinary medical device business built around Spryng, an injectable joint treatment for osteoarthritic dogs and horses. The company reported an approximate $10 million net loss for the year ended March 31, 2026 and an accumulated deficit of about $102.0 million.

Liquidity is a key concern: cash and cash equivalents were roughly $201,000 as of March 31, 2026, which management expects to fund operations for about one month, or roughly four months if up to $1.5 million is invested under an existing purchase option. As of June 29, 2026, non‑affiliate common stock had an aggregate market value of $12,126,991, with 37,594,245 shares outstanding. The report emphasizes dependence on Spryng, new distribution relationships with Vedco and Clipper, an exclusive licensing deal for VetStem’s PrecisePRP, and a portfolio of patents, trade secrets, and trademarks. Extensive risk factors highlight continuing losses, financing needs, prior Nasdaq delisting and trading on OTCQX, strong competition in animal health, manufacturing and distribution risks, and cybersecurity oversight processes.